ProKidney Corp.

Equities

PROK

KYG7S53R1049

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:03:00 2024-05-02 pm EDT			5-day change	1st Jan Change
2.17 ^USD	+0.46%		-20.30%	+21.35%

Mar. 25	ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations	CI
Mar. 22	ProKidney Posts Wider 2023 Loss	MT

ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 04:23 pm EDT

ProKidney Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 9.12 million compared to USD 22.13 million a year ago. Basic loss per share from continuing operations was USD 0.14.
For the six months, net loss was USD 18.78 million compared to USD 89.62 million a year ago. Basic loss per share from continuing operations was USD 0.29.

Latest news about ProKidney Corp.

ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations	Mar. 25	CI
ProKidney Posts Wider 2023 Loss	Mar. 22	MT
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
BofA Securities Downgrades ProKidney to Neutral From Buy, Cuts Price Target to $2 From $8	Jan. 02	MT
ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer	Nov. 30	CI
Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer	Nov. 30	CI
ProKidney Files $500 Million Mixed Shelf	Nov. 22	MT
Prokidney Insider Sold Shares Worth $9,498,584, According to a Recent SEC Filing	Nov. 21	MT
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	Nov. 20	MT
Sector Update: Health Care	Nov. 20	MT
Top MIdday Gainers	Nov. 20	MT
ProKidney Corp. announces an Equity Buyback for 7,256,367 shares, for $9.5 million.	Nov. 20	CI
ProKidney Corp. authorizes a Buyback Plan.	Nov. 18	CI
Transcript : ProKidney Corp., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
ProKidney Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ProKidney Corp. Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD	Nov. 13	CI
ProKidney Corp. Announces Executive Changes	Nov. 13	CI
Prokidney Insider Sold Shares Worth $334,948, According to a Recent SEC Filing	Nov. 09	MT
Prokidney Insider Sold Shares Worth $567,573, According to a Recent SEC Filing	23-10-27	MT
Prokidney Insider Sold Shares Worth $899,963, According to a Recent SEC Filing	23-10-24	MT
Prokidney Insider Sold Shares Worth $1,205,390, According to a Recent SEC Filing	23-10-19	MT
Prokidney Insider Sold Shares Worth $1,391,817, According to a Recent SEC Filing	23-10-16	MT
Prokidney Insider Sold Shares Worth $9,299,000, According to a Recent SEC Filing	23-09-21	MT
Transcript : ProKidney Corp. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 12:15 PM	23-09-11
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart ProKidney Corp.

Duration

Period

More charts

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.16 USD

Average target price

4.2 USD

Spread / Average Target

+94.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROKIDNEY CORP.	+21.35%	138M
MODERNA, INC.	+25.11%	42.68B
IQVIA HOLDINGS INC.	-2.85%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+7.33%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-20.41%	18.96B
MEDPACE HOLDINGS, INC.	+28.98%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.76%	11.95B
BIO-TECHNE CORPORATION	-1.43%	11.55B

Other Biotechnology & Medical Research